| Literature DB >> 26324018 |
Ludwig J Dubois1, Raymon Niemans2, Simon J A van Kuijk2, Kranthi M Panth2, Nanda-Kumar Parvathaneni3, Sarah G J A Peeters2, Catharina M L Zegers2, Nicolle H Rekers2, Marike W van Gisbergen2, Rianne Biemans2, Natasja G Lieuwes2, Linda Spiegelberg2, Ala Yaromina2, Jean-Yves Winum4, Marc Vooijs2, Philippe Lambin2.
Abstract
Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis. Detection of hypoxia, preferably in a non-invasive manner, could therefore predict treatment outcome and serve as a tool to individualize treatment. This review gives an overview of recent literature on hypoxia imaging markers currently used in clinical trials. Furthermore, recent progress made in targeting hypoxia (hypoxia-activated prodrugs) or hypoxia response (carbonic anhydrase IX inhibitors) is summarized. Last, window-of-opportunity trials implementing non-invasive imaging are proposed as an important tool to prove anti-tumour efficacy of experimental drugs early during drug development.Entities:
Keywords: Carbonic anhydrase IX; Hypoxia; Imaging; Therapy; Window-of-opportunity trial
Mesh：
Year: 2015 PMID： 26324018 DOI： 10.1016/j.radonc.2015.08.022
Source DB: PubMed Journal: Radiother Oncol ISSN： 0167-8140 Impact factor: 6.280